John A. Borgeson serves as the Executive Vice President, Chief Financial Officer, and Secretary at KODIAK SCIENCES INC, a biopharmaceutical company focused on developing novel therapies for retinal diseases. In his role, Borgeson is responsible for overseeing the company's financial operations, strategic planning, and corporate governance. He plays a crucial role in guiding KODIAK SCIENCES INC through its growth phases, ensuring financial stability and compliance with regulatory requirements. Borgeson brings a wealth of experience to his position, having spent over two decades in the biotechnology and pharmaceutical industries. Prior to joining KODIAK SCIENCES INC, he held various senior financial positions at notable companies such as Genentech, where he served as the Vice President of Finance and Chief Accounting Officer. During his tenure at Genentech, Borgeson was instrumental in managing the company's financial strategy during its acquisition by Roche in 2009. His expertise in financial management and strategic planning has been pivotal in driving KODIAK SCIENCES INC's success in developing innovative treatments for patients with retinal diseases. In addition to his professional achievements, Borgeson is recognized for his leadership and commitment to advancing the biopharmaceutical industry. He holds a Bachelor of Science degree in Business Administration from the University of California, Berkeley, and is a Certified Public Accountant. Under his financial stewardship, KODIAK SCIENCES INC continues to make significant strides in its mission to deliver transformative therapies, solidifying its position as a leader in the field of retinal disease treatment.